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LETTERS
CERVICAL SCREENING
Women under 25 should be 
offered screening
There may be several reasons why cervical 
screening coverage in young women 
has fallen yet again, including problems 
with access to appointments with general 
practitioners, but the new policy not to 
screen women aged 20-24 can hardly have 
helped.1 It was announced with the message 
that screening that age group caused more 
harm than good, which is unlikely to 
encourage them to accept their invitations 
from age 25. Prevalence of carcinoma in 
situ (CIN3) has increased in women aged 
20-24 (figure), which is consistent with more 
women in recent birth cohorts starting 
sexual activity in their mid-teens.
The new policy will add more than 3000 
women with untreated CIN3 to the larger 
numbers failing to accept their invitations 
later on. We accept that any degree of 
CIN may regress, invasive cervical cancer 
(ICC) is rare in women under 25, and 
screening does little to reduce its incidence 
in such young women. However, ICC can 
develop within a couple of years of missed 
high-grade cytology, failure to investigate 
cytological abnormalities, or incomplete 
treatment,2 emphasising the importance of 
treating high-grade CIN when it is found.
Screening in the UK has been highly 
successful since it was centrally organised 
in 1988: incidence and mortality have 
fallen by more than 40% despite increased 
risk of disease.3 This has been achieved by 
treating high-grade CIN, particularly CIN3, 
in young women. The peak prevalence of 
CIN3 is in women aged 25-29 amongst 
whom the fall in coverage has been greatest.
ICC is more difficult to prevent in young 
women because there are less screening 
opportunities to treat these lesions before 
they become invasive.4 The peak incidence 
of ICC in the screening age groups is now 
in women aged 35-39. Most of these cancers 
are detected by screening at an early and 
treatable stage.4
Decisions about treatment of CIN 
should be based on a balance between risk 
of progression, likelihood of regression, 
and risk of treatment.5 Women should be 
informed about the risk of high-grade CIN, 
its greater frequency in young women, the 
importance of surveillance of low grade 
abnormalities, and the fact that an epidemic 
of cervical cancer has been prevented by 
screening wo   men when they were young.2 
General practitioners and clinics should not 
be prevented from screening women whom 
they believe to be at risk if those women 
themselves want to be screened.
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MALIGNANT PLEURAL EFFUSION
Video assisted thoracoscopic 
surgery is still the standard
We were surprised that Rahman et al did not 
mention video assisted thoracoscopic surgery 
in investigating malignant pleural effusion.1 
For more than 15 years it has been the 
cornerstone of investigation and palliation 
of such disease in those fit for general 
anaesthesia.1 Complex loculated effusions 
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can be evacuated and the pleural cavity 
debrided appropriately.
The systematic examination of the 
mediastinum, pericardium, and diaphragm 
as well as the visceral pleura and underlying 
lung is easily and safely performed. Multiple 
targeted pleural biopsies can be performed, 
as well as biopsies of mediastinal nodes as 
required.
The expansion of the lung in response to 
positive pressure ventilation determines the 
appropriate method of palliation. If there is 
apposition of the visceral and parietal pleura 
talc pleurodesis is the method of choice, 
where this does not occur talc is detrimental 
and potentially leads to empyema. In most 
series, surgical talc insufflation provides 
superior palliation to talc slurry.
Lastly, as a thoracic surgeon operating on 
a large volume of patients with malignant 
mesothelioma, video assisted thoracoscopic 
surgery represents an excellent staging tool 
and determinant of the best surgical option 
for such patients.
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Tuberculosis is differential 
diagnosis in developing world
In countries with a high prevalence 
of tuberculosis, malignancy is still the 
commonest cause of bloody pleural effusion, 
but the next most common causes are 
tuberculosis and trauma.1 2 Accordingly, 
in the absence of associated stigmata of 
malignancy, even pleural effusion whose 
outward appearance is highly suggestive 
of malignancy should be considered to be 
potentially tuberculous, and appropriate tests 
should be instigated if initial investigations 
do not confirm malignancy. In this context, 
appropriate tests for tuberculosis include 
not only closed biopsy (with histology and 
culture),1 but also measurement of  interferon 
! in the pleural fluid.3
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ANIMAL TESTING
A broader view of animal 
research
Perel et al examined only immediate 
preclinical testing of new drug therapies,1 
but animal research aids medical science 
in many more ways. Animal studies play a 
part in the initial development of candidate 
drugs, and the development and testing of 
medical devices and surgical procedures. 
Even more crucial, animal research informs 
clinical research by building the foundation 
of biological knowledge. Basic research 
that expands our understanding of how 
life systems function indicates to clinicians 
not only what direction to pursue but what 
directions are possible.
Although animal research informs clinical 
research, its circumstances and experimental 
goals differ from those of clinical research. 
Thus their protocols and experimental 
designs necessarily differ. Animal studies 
generally seek a mechanism of action for 
treatment, rather than treatment efficacy. 
They are usually conducted on defined, 
genetically homogenous subjects with 
near perfect compliance, as opposed to 
the large scale diversity of genetics and 
behaviour of a clinical population. Some 
clinically necessary procedures, such as 
double blinding, serve little purpose in an 
animal study, since rats are not susceptible 
to the placebo effect. Furthermore, accepted 
standards for animal welfare as well as many 
national and institutional protocols insist 
that sample sizes of animal studies be small. 
Despite these differences, the protocol used 
by Perel et al to determine that the animal 
studies were of “poor” 
quality was based, 
for the most part, 
on standards 
meant for large 
clinical trials.
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Studies in animals should be 
more like those in humans
The settings of animal studies are very 
different from those of therapeutic studies 
in human patients.1 They need to be more 
similar.
In clinical studies, a human subjects 
committee must approve the methods of 
the study, determining that it is of sufficient 
power to produce a meaningful result and 
that the risk:benefit ratio is acceptable. 
There should be animal subject committees 
similarly to scrutinise drug trials in animals. 
The task of such committees would be 
to assess sample size, randomisation of 
treatments, blinding of observers, selection 
of animal subjects, statistical methods, and 
elimination of biases that may be introduced 
by the pharmaceutical company that 
sponsors the work.
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BORDER CROSSING
Alliance of regulators addresses 
professional mobility
Two articles reflect recent media interest 
in health tourism in the context of the 
European Commission consultation on 
health services in Europe.1 2 What neither 
article addresses is the equally important 
issue of professional mobility that provides 
the other focus of the commission’s 
consultation.
In 2005, over 7000 healthcare 
professionals from the European Economic 
Area registered with UK regulatory bodies 
for the first time so that they could work 
in this country. The United Kingdom has 
undoubtedly benefited from this high 
degree of professional mobility, with many 
dedicated individuals contributing positively 
to UK health care. But the EU rules that 
facilitate this level of mobility must also 
ensure proper protection for patients and the 
public.
The Alliance of UK Health Regulators 
on Europe (AURE) brings together the 
10 health and social care regulators in the 
UK to work collaboratively on European 
issues affecting patient and client safety. 
While ensuring that professionals are able to 
benefit from their rights to free movement, 
regulators must also ensure that the few 
with impaired fitness to practise do not put 
patients at risk. European legislation must 
give regulators the tools to enable them to 
do this.
For crossborder healthcare to be safe 
and effective, greater information must 
be available for patients, professionals 
and regulators. In AURE’s response to 
the European Commission’s consultation 
(launched on 23 January), we called on 
the European Commission to propose 
a legal duty on regulators across the EU 
to exchange registration and disciplinary 
information and to act on it. This action, 
supporting the role of national regulators, 
would make a real contribution to 
enhancing patient safety in the EU.
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REPUTATIONS
Slow handclapping and the 
sound of silence
Much as I like the idea of slow handclapping 
speakers who do not declare their conflict(s) 
of interest,1 this method of protest can really 
only be practised by the few that pay their 
own way to attend the meeting. Too many 
snouts are in the trough to expect anything 
other than shameful silence.
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